Copelan Edward A, Grunwald Michael R, Druhan Lawrence J, Avalos Belinda R
Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.
Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.
Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):143-9. doi: 10.1016/j.hemonc.2015.09.003. Epub 2015 Oct 11.
Most patients with acute myeloid leukemia can be induced into complete remission, but postremission treatment is required for cure. The choice of postremission therapy in a majority of nonelderly patients, between intensive chemotherapy and allogeneic hematopoietic cell transplantation, is largely determined by the results of conventional cytogenetic analysis. In 45% of patients with a normal karyotype, the presence or absence of specific molecular mutations should be used to determine the prognosis and postremission treatment. In addition, the identification of mutations may indicate a role for targeted intervention, including following transplantation.
大多数急性髓系白血病患者可诱导进入完全缓解期，但要治愈则需要缓解后治疗。在大多数非老年患者中，缓解后治疗在强化化疗和异基因造血细胞移植之间的选择，很大程度上取决于传统细胞遗传学分析的结果。在45%核型正常的患者中，应根据特定分子突变的有无来确定预后及缓解后治疗方案。此外，突变的鉴定可能表明靶向干预的作用，包括移植后的干预。
